An overview of 5-HT₃ receptor antagonists as a treatment option for irritable bowel syndrome with diarrhea

References

• Longstreth GF, Grant Thompson W, Chey WD, et al. Functional bowel disorders. Gastrenterology. 2006;130:1480–1491.
   PubMed Web of Science ®Google Scholar
• Nakai A, Diksic M, Kumakura Y, et al. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2005;2:212–221.
   Google Scholar
• Min YW, Rhee PL. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol. 2015 May 8;3:136–142. DOI:10.1177/1756283X15572580
   Google Scholar
• Gros M, Gros B, Mesonero JE, et al. Neurotransmitter dysfunction in irritable bowel syndrome: emerging approaches for management. J Clin Med. 2021 Jul 31;10:3429. DOI:10.3390/jcm10153429
   PubMed Web of Science ®Google Scholar
• Corsetti M, Whorwell P. Novel pharmacological therapies for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2016 Jul;7(10):807–815.
   Google Scholar
• Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;7(104):1831–1843.
   Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;7(7):712–721.
   Google Scholar
• Nee J, Lembo A. Review article: current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). Aliment Pharmacol Ther. 2021;54:63–74.
   Web of Science ®Google Scholar
• Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66(5):966–974. DOI:10.1136/gutjnl-2016-313425
   PubMed Web of Science ®Google Scholar
• Juza R, Vlcek P, Mezeiova E, et al. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev. 2020;5(5):1593–1678.
   Google Scholar
• White AR, Filshie J, Cummings TM. Clinical trials of acupuncture: consensus recommendations for optimal treatment, sham controls and blinding. Complement Ther Med. 2001;4(4):237–245.
   Google Scholar
• Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1 1This study was registered with ClinicalTrials.Gov (trial registry no. NCT00006157). Gastroenterology. 2003;1(1):19–31.
   Google Scholar
• Rexwinkel R, Vlieger AM, Saps M, et al. A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. Eur J Pediatr. 2022;181:2603–2617.
   PubMed Web of Science ®Google Scholar
• Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: current knowledge, challenges and opportunities. World J Gastroenterol. 2018;24:2211–2235. DOI:10.3748/wjg.v24.i21.2211. PMID: 29881232; PMCID: PMC5989237. 2018.
   PubMed Web of Science ®Google Scholar
• Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137:1261–1269. DOI:10.1053/j.gastro.2009.06.060. Epub 2009 Jul 31. PMID: 19596010; PMCID: PMC2827243.
   PubMed Web of Science ®Google Scholar
• Paine P. Review article: current and future treatment approaches for pain in IBS. Aliment Pharmacol Ther. 2021;54:75–88.
   Web of Science ®Google Scholar
• Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther. 1992;6(3):273–289.
   PubMed Web of Science ®Google Scholar
• Guzel T, Mirowska-Guzel D. The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy. Molecules. 2022;5(5):1680.
   Google Scholar
• Gershon MD, Liu MT. Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil. 2007;19(19):19–24.
   PubMedGoogle Scholar
• I S V, Tsouklidis N, Kumar R, et al. How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome. Cureus. 2020;9(12):9871. DOI:10.7759/cureus.9871
   Google Scholar
• Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007 Jan;132(1):397–414.
   PubMed Web of Science ®Google Scholar
• Waclawiková B, Bullock A, Schwalbe M, et al. Gut bacteria-derived 5-hydroxyindole is a potent stimulant of intestinal motility via its action on L-type calcium channels. PLoS Biol. 2021;1(1):3001070.
   Google Scholar
• Golubeva AV, Joyce SA, Moloney G, et al. Microbiota-related changes in bile acid & tryptophan metabolism are associated with gastrointestinal dysfunction in a mouse model of autism. EBioMedicine. 2017 Oct 24;24:166–178. DOI:10.1016/j.ebiom.2017.09.020
   PubMed Web of Science ®Google Scholar
• Mishima Y, Ishihara SE. Microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome. Int J Mol Sci. 2021 Sep 23;22:10235. DOI:10.3390/ijms221910235
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Lo M, Hosoya T, et al. Experimental colitis alters expression of 5-HT receptors and transient receptor potential vanilloid 1 leading to visceral hypersensitivity in mice. Lab Invest. 2012;92:769–782.
   PubMed Web of Science ®Google Scholar
• Utsumi D, Matsumoto K, Amagase K, et al. 5-HT3 receptors promote colonic inflammation via activation of substance P/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis. Br J Pharmacol. 2016 Jun;11(173):1835–1849.
   Google Scholar
• Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002 Apr;71(4):533–554.
   PubMed Web of Science ®Google Scholar
• Irving H, Turek I, Kettle C, et al. Tapping into 5-HT3 receptors to modify metabolic and immune responses. Int J Mol Sci. 2021 Nov 2;22:11910. DOI:10.3390/ijms222111910
   PubMed Web of Science ®Google Scholar
• Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992 Aug;67:732–738.
   PubMed Web of Science ®Google Scholar
• Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011 Jun;130:338–347.
   PubMed Web of Science ®Google Scholar
• Fakhfouri G, Rahimian R, Dyhrfjeld-Johnsen J, et al. 5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface. Pharmacol Rev. 2019 Jul;71:383–412.
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhang Y, Chen F, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018;18. DOI:10.1186/s12876-017-0734-2
   Web of Science ®Google Scholar
• Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol. 1998 May;274(5):G827–31.
   PubMedGoogle Scholar
• Funatsu T, Takeuchi A, Hirata T, et al. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur J Pharmacol. 2007 Nov;573(1–3):14.
   Web of Science ®Google Scholar
• Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008 May;20(5):557–565.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014 Jun;12(6):953–9.e4.
   PubMed Web of Science ®Google Scholar
• Ida M, Nishida A, Akiho H, et al. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea. Biopsychosoc Med. 2017 Mar;11. DOI:10.1186/s13030-017-0093-9
   Web of Science ®Google Scholar
• Ida, Motoko. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. Biopsychosoc Med. Mar 2017;11(7). DOI:10.1186/s13030-017-0092-x
   Google Scholar
• Fukudo S, Kinoshita Y, Okumura T. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;2:358–366.
   Google Scholar
• Qi Q, Zhang Y, Chen F, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018 Jan;18. DOI:10.1186/s12876-017-0734-2
   Web of Science ®Google Scholar
• Yarker YE, McTavish DAUOITUINAVIBAT. Granisetron. Drugs. 1994;48:761–793.
   PubMedGoogle Scholar
• Times O. FDA approval for sancuso for prevention of chemotherapy-induced nausea & vomiting. Oncol Times. 2008 Oct 25;30(20): 38. DOI:10.1097/01.COT.0000340700.76695.b0
   Google Scholar
• Elliott P, Seemungal BM, Wallis DI. Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jun;341. DOI:10.1007/BF00171729
   Web of Science ®Google Scholar
• Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Apr;7:175–180.
   PubMed Web of Science ®Google Scholar
• Louvel D, Delvaux M, Staumont G, et al. Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? Gastroenterology. 1996 Feb;110:351–361.
   PubMed Web of Science ®Google Scholar
• Chen L, Ilham SJ, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth Pain Med. 2017 Jan;7. DOI:10.5812/aapm.42747
   Google Scholar
• Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut. 2002 Jul;51:i81–86.
   PubMed Web of Science ®Google Scholar
• Kuiken SD, Tytgat GN, Boeckxstaens GE. Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders–the clinical evidence. Aliment Pharmacol Ther. 2005 Mar;21:633–651.
   PubMed Web of Science ®Google Scholar
• Bueno L, de Ponti F, Fried M, et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol Motil. 2007 Jan;19:89–119.
   PubMed Web of Science ®Google Scholar
• Griddine A, Bush JS. Ondansetron. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Feb 15.
   Google Scholar
• Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Vol. 1996;10(2):595–599.
   Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea Gut. 2014;63(10):1617–1625. DOI:10.1136/gutjnl-2013-305989
   PubMed Web of Science ®Google Scholar
• Nakade Y, Fukuda H, Iwa M, et al. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physiol Gastrointest Liver Physiol. 2007;292(4):1037–1044. DOI:10.1152/ajpgi.00419.2006
   PubMed Web of Science ®Google Scholar
• Plasse TF, Barton G, Davidson E, et al. Bimodal release ondansetron improves stool consistency and symptomatology in diarrhea-predominant irritable bowel syndrome a randomized, double-blind, trial. Am J Gastroenterol. 2020;115(9):1466–1473. DOI:10.14309/ajg.0000000000000727
   PubMed Web of Science ®Google Scholar
• Levy R, Corbo J, Prasad S. An antiemetic for irritable bowel syndrome? The Journal of family practice. 2014;63(10):600–602.
   PubMed Web of Science ®Google Scholar
• Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2000;14(6):775–782.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Lummis SC. The 5-HT 3 receptor as a therapeutic target. Expert Opin Ther Targets. 2007;11(4):527.
   PubMed Web of Science ®Google Scholar
• Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13(Suppl 2):77–82. DOI:10.1046/j.1365-2036.1999.00010.x
   PubMedGoogle Scholar
• Viramontes BE, Camilleri M, McKinzie S, et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(9):2671–2676.
   PubMed Web of Science ®Google Scholar
• Harris LA, Chang L. Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome. Womens Health (Lond). 2007;3(1):15–27. DOI:10.2217/17455057.3.1.15
   PubMedGoogle Scholar
• Online D. Granisetron: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB00889
   Google Scholar
• Philippines MIMS. Ramosetron: indication, dosage, side effect, precaution. https://www.mims.com/philippines/drug/info/ramosetron?mtype=generic
   Google Scholar
• MedlinePlus. Granisetron: MedlinePlus drug information. https://medlineplus.gov/druginfo/meds/a601211.html
   Google Scholar
• DrugBank Online, n.d. Ramosetron: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB09290
   Google Scholar